Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.

Martin F KaiserAndrew HallKatrina WalkerAmy SherborneRuth M De TuteNicola NewnhamSadie RobertsEmma InglesonKristian M Bowles Mamta GargAnand LokareChristina Messiou Richard S Houlston Graham H Jackson Curly T C M Morris Guy PrattRoger G OwenMark T DraysonSarah R Brown Matthew W Jenner

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

Our results suggest that Dara-CVRd induction and extended post-ASCT Dara-VRd consolidation markedly improve PFS for UHiR NDMM patients over conventional management, supporting further evaluation of this strategy.

Keyphrases

multiple myeloma
newly diagnosed
end stage renal disease
low dose
high dose
chronic kidney disease
ejection fraction
peritoneal dialysis
prognostic factors
stem cell transplantation
patient reported outcomes